Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProstACT TARGET: 177Lu-TLX591 + EBRT in Recurrent Oligometastatic Prostate Cancer
NCT05146973Phase 2Completed
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 177lu-rosopatamab in prostate cancer (PCa), sponsored by Telix Pharmaceuticals Limited. Primary endpoint: Prostate Specific Antigen Progression Free Survival at 2 years. Started Aug 2022; status: completed.
02
Drugs
177lu-rosopatamab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05146973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05146973.